Amphastar Pharmaceuticals Financial Activities - Other 2012-2025 | AMPH

Amphastar Pharmaceuticals financial activities - other from 2012 to 2025. Financial activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the financing activities section of the Cash Flows Statement.
Amphastar Pharmaceuticals Annual Financial Activities - Other
(Millions of US $)
2024 $-1
2023 $-25
2022 $0
2021 $-56
2020 $0
2019 $18
2018 $38
2017 $N/A
2016 $N/A
2015 $N/A
2014 $-3
2013 $-2
2012 $0
2011 $-1
2009 $N/A
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.178B $0.732B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.298B 6.98
Dr Reddy's Laboratories (RDY) India $12.071B 21.91
BridgeBio Pharma (BBIO) United States $6.397B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.850B 15.02
Bausch Health Cos (BHC) Canada $1.681B 1.24
Taysha Gene Therapies (TSHA) United States $0.599B 0.00
Personalis (PSNL) United States $0.443B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00